Leandro Barile Agati

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro et al. · The Lancet · 2021 · 252 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Zika and Chikungunya Virus and Risk for Venous Thromboembolism

Eduardo Ramacciotti, Leandro Barile Agati, Valéria Cristina Resende Aguiar et al. · Clinical and Applied Thrombosis/Hemostasis · 2019 · 54 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +13

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial

André Luiz Malavasi Longo de Oliveira, Renata Fernanda de Oliveira Pereira, Leandro Barile Agati et al. · Clinical and Applied Thrombosis/Hemostasis · 2022 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial

Rodrigo Bruno Biagioni, Renato D. Lópes, Leandro Barile Agati et al. · American Heart Journal · 2020 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial

Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro et al. · American Heart Journal · 2021 · 19 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15